TANGO: Switch to DTG/3TC Maintains Virologic Suppression at Wk 48 Across Patient Demographics and Baseline Third Agent Classes

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
Switching from a TAF-based regimen to DTG/3TC maintains virologic suppression across patient subgroups regardless of patient demographics, disease characteristics, or baseline third agent.
Format: Microsoft PowerPoint (.ppt)
File Size: 191 KB
Released: November 8, 2019


Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Opciones de cuidado clínico (CCO) presenta a la Dra. Alicia Piñeirúa que explica los principales factores que hay que tener en cuenta a la hora de optimizar el tratamiento antirretroviral en el marco de la supresión viral en pacientes que viven con el VIH y la osteopenia

person default Alicia Piñeirúa Menéndez, MD, MPH Released: August 2, 2022

SIMPL’HIV: switch from standard ART to DTG + FTC in virologically suppressed PWH through Wk 144, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 2, 2022

Dr Darcy Wooten and Clinical Care Options (CCO): Data are emerging on strategies to manage ART-associated weight gain and metabolic complications

Darcy Wooten, MD Released: August 1, 2022

Expert insights on new, emerging, and potential future long-acting antiretroviral agents for HIV treatment and prevention, from Clinical Care Options (CCO)

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings